ClinicalTrials.gov
public full text
Public Domain
CPET in CF Patients With One G551D Mutation Taking VX770
Ivacaftor will restore CFTR function in treated CF patients with the G551D mutation. Improvement in ventilation, salt balance and well-being will contribute to better exercise capacity at all levels of lung function. While potential improvements may be variable across the spectrum of lung function, even small gains at low levels of FEV1 may have significant benefit for some subjects.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- 42 CFR Part 88 — World Trade Center Health Program#509938
- 49 CFR Part 1112 — Modified Procedures#511988
- 20 CFR Part 431 — Protection of Human Subjects#506638
- 33 CFR Part 337 — Practice and Procedure#508850
- 28 CFR Part 813 — Guidance Development Procedures#507797
Record · ID 854269
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive